Dharti Proteins closes trading window ahead of Q2FY27 results

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Trading window closed from October 1, 2026
  • Restriction applies until 48 hours after Q2FY27 results
  • Covers Directors, Promoters, and Specified Connected Persons
  • Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015
powered bylight_fuzz_icon
51708636

*this image is generated using AI for illustrative purposes only.

Dharti Proteins Limited closed its trading window for equity shares starting October 1, 2026. The restriction applies to all Directors, Promoters, Designated Persons, and Specified Connected Persons. This closure remains in effect until 48 hours after the company declares its unaudited financial results for the quarter and half-year ending September 30, 2026.

The decision complies with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, and the company's internal code of conduct. These regulations mandate that insiders refrain from dealing in securities during periods when price-sensitive information is unpublished. The trading window will reopen once the results are publicly announced and the mandatory cooling-off period expires.

Regulatory compliance and scope

The intimation was filed with BSE Limited on September 23, 2026. The company identified specific categories of personnel bound by this restriction. All designated persons and their immediate relatives are advised not to trade in the securities of Dharti Proteins during the closure period.

Detail Information
Company Dharti Proteins Limited
Window Closure Start October 1, 2026
Window Closure End 48 hours post-results
Reporting Period Q2FY27 (Quarter/Half-year ending Sep 30, 2026)
Regulatory Basis SEBI (PIT) Regulations, 2015

The company noted that the date of the Board Meeting for considering and approving these financial results will be communicated in due course. Until then, the prohibition on trading stands firm to ensure market integrity and prevent potential misuse of unpublished price-sensitive information.

When will Dharti Proteins announce the specific date for the Board Meeting to approve the Q2FY27 financial results?

How might the upcoming unaudited results for the quarter ending September 30, 2026, impact investor sentiment and stock volatility upon release?

Are there any pending regulatory filings or material events expected from Dharti Proteins before the trading window reopens?

like17
dislike

Dharti Proteins adds director regularization to Sept 28 AGM notice

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Dharti Proteins adds resolution to regularize Mr. Karnik Shasankan Pillai as director
  • Corrigendum issued due to inadvertent omission in original Sept 1 notice
  • AGM scheduled for Sept 28, 2026 via VC/OAVM with e-voting open Sept 25-27
  • Agenda also includes ₹100 crore convertible loan proposal from MD
powered bylight_fuzz_icon
49810886

*this image is generated using AI for illustrative purposes only.

Dharti Proteins Limited issued a corrigendum on September 9, 2026, to its Annual General Meeting notice scheduled for September 28, 2026. The update adds the resolution for the regularization of Mr. Karnik Shasankan Pillai as a Non-Executive Non-Independent Director to the agenda.

The company cited an inadvertent omission in the original notice dated September 1, 2026. The addendum serves as an integral part of the original notice and will be included in the remote e-voting facility from September 25 to September 27, 2026. Newspaper advertisements for the addendum were published in “Free Press, Gujarat” and “Lokmitra” on September 10, 2026.

Updated Board Composition

The AGM agenda now includes Resolution No. 13 for the appointment of Mr. Karnik Shasankan Pillai (DIN: 08529650). He was initially appointed as an Additional Director by the Implementation and Monitoring Committee on December 3, 2025.

Director Name DIN Role Term Start
Mr. Karnik Shasankan Pillai 08529650 Non-Executive Non-Independent Director December 3, 2025
Ms. Shubhangi Janifer 09125625 Independent Director December 3, 2025
Ms. Poorva Jain 11386684 Independent Director December 3, 2025
Mrs. Chitra Naraniwal 09077116 Independent Director December 3, 2025

Mr. Jatinbhai Ramanbhai Patel (DIN: 06973337) retires by rotation and offers himself for re-appointment as Managing Director. He currently holds 5% of the company’s equity shares.

Capital Structure and Borrowing

The AGM agenda includes critical financial resolutions:

  • Convertible Loan: Approval for an unsecured loan of up to ₹100 crore from Managing Director Jatinbhai Ramanbhai Patel. The loan carries an option to convert outstanding principal and/or interest into equity shares at a later date, subject to SEBI guidelines.
  • Borrowing Limit: Enhancement of borrowing limits under Section 180(1)(c) of the Companies Act, 2013, to a maximum of ₹5,000 crore.
  • Investment Limit: Enhancement of limits for loans, guarantees, and investments under Section 186 of the Companies Act, 2013, to an aggregate amount not exceeding ₹5,000 crore.

These limits are significantly higher than the current prescribed limits based on paid-up share capital and free reserves, reflecting the company’s planned expansion in edible oils and agricultural processing.

Corporate Governance Updates

The company is undergoing several governance refreshments:

  • Secretarial Auditor: Appointment of M/s. Dharti Patel & Associates as Secretarial Auditors for five financial years (FY26 to FY30).
  • Internal Auditor: As previously reported, M/s. Mikil Vora & Associates was appointed as internal auditor for FY27 to FY31 following the resignation of PSG & Associates.
  • MOA/AOA Adoption: Adoption of new Memorandum and Articles of Association aligned with the Companies Act, 2013. This includes altering the Object Clause to explicitly cover manufacturing edible oils, processing agricultural produce, and dealing in food products.

What the Numbers Show

The proposed ₹100 crore convertible loan from the Managing Director represents a strategic shift in capital sourcing. With the company’s paid-up share capital at ₹50 lakh and no free reserves or securities premium as of March 31, 2026, this related-party financing provides immediate liquidity without diluting existing shareholders immediately. The conversion option aligns the director’s interests with long-term equity value creation, while the ₹5,000 crore borrowing limit authorizes substantial leverage for future operational scaling.

Meeting Details

  • Date: September 28, 2026
  • Time: 11:00 am
  • Mode: Video Conferencing / OAVM
  • E-Voting Period: September 25, 2026 (9:00 am) to September 27, 2026 (5:00 pm)
  • Record Date: September 21, 2026

How will the proposed ₹100 crore convertible loan from the Managing Director impact existing shareholder equity upon conversion, and what are the specific valuation metrics for this equity swap?

Given the massive increase in borrowing limits to ₹5,000 crore against a paid-up capital of only ₹50 lakh, what specific expansion projects or acquisitions is Dharti Proteins planning to finance with this leverage?

What is the strategic rationale behind appointing Mr. Karnik Shasankan Pillai as a Non-Executive Non-Independent Director, and how does his background align with the company's new focus on edible oils and agricultural processing?

like20
dislike

More News on Dharti Proteins Limited